Breaking the therapeutic ceiling in drug development in ulcerative colitis

2020, Ulcerative colitis, Nat Rev Dis Primers, 6, 73, 10.1038/s41572-020-00215-4

Harbord, 2017, Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management, J Crohns Colitis, 11, 769, 10.1093/ecco-jcc/jjx009

Sabino, 2019, New biologics and small molecules in inflammatory bowel disease: an update, Therap Adv Gastroenterol, 12, 10.1177/1756284819853208

Burisch, 2019, Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort—an epi-IBD study, J Crohns Colitis, 13, 198, 10.1093/ecco-jcc/jjy154

Alatab, 2020, The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet Gastroenterol Hepatol, 5, 17, 10.1016/S2468-1253(19)30333-4

Castaño-Milla, 2014, Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis, Aliment Pharmacol Ther, 39, 645, 10.1111/apt.12651

Rutgeerts, 2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516

Sandborn, 2012, Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 142, 257, 10.1053/j.gastro.2011.10.032

Sandborn, 2014, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 85, 10.1053/j.gastro.2013.05.048

Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734

Dotan, 2020

Peyrin-Biroulet, 2020

Sands, 2019, Ustekinumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 381, 1201, 10.1056/NEJMoa1900750

Sandborn, 2017, Tofacitinib as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 376, 1723, 10.1056/NEJMoa1606910

Feagan, 2020

Sandborn, 2020

Torres, 2012, Ulcerative colitis as a progressive disease: the forgotten evidence, Inflamm Bowel Dis, 18, 1356, 10.1002/ibd.22839

Johnson, 2020, Trends and characteristics of clinical trials participation for inflammatory bowel disease in the United States: a report from IBD Partners, Crohns Colitis 360, 2

Raine, 2020, Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?, Lancet Gastroenterol Hepatol, 5, 794, 10.1016/S2468-1253(20)30210-7

Singh, 2020, First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis, Clin Gastroenterol Hepatol, 18, 2179, 10.1016/j.cgh.2020.01.008

Sands, 2019, Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis, N Engl J Med, 381, 1215, 10.1056/NEJMoa1905725

Pouillon, 2020, Head-to-head trials in inflammatory bowel disease: past, present and future, Nat Rev Gastroenterol Hepatol, 17, 365, 10.1038/s41575-020-0293-9

West, 2017, Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease, Nat Med, 23, 579, 10.1038/nm.4307

Bertani, 2020, Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab, Aliment Pharmacol Ther, 52, 284, 10.1111/apt.15870

Verstockt, 2019, Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease, EBioMedicine, 40, 733, 10.1016/j.ebiom.2019.01.027

Verstockt, 2019, Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease, Aliment Pharmacol Ther, 49, 572, 10.1111/apt.15126

Noor, 2020, Personalised medicine in Crohn's disease, Lancet Gastroenterol Hepatol, 5, 80, 10.1016/S2468-1253(19)30340-1

Buer, 2018, Combining anti-TNF-α and vedolizumab in the treatment of inflammatory bowel disease: a case series, Inflamm Bowel Dis, 24, 997, 10.1093/ibd/izx110

Kwapisz, 2020, Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center, Clin Gastroenterol Hepatol, 19, 616, 10.1016/j.cgh.2020.02.017

Glassner, 2020, The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study, J Dig Dis, 21, 264, 10.1111/1751-2980.12867

Yang, 2020, Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease, Aliment Pharmacol Ther, 51, 1031, 10.1111/apt.15719

Fumery, 2020, Letter: combination of biologics in inflammatory bowel diseases, Aliment Pharmacol Ther, 52, 566, 10.1111/apt.15891

Privitera, 2021, Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease, J Crohns Colitis, 15, 335, 10.1093/ecco-jcc/jjaa149

Narula, 2020, Ileal and rectal ulcer size affects the ability to achieve endoscopic remission: a post hoc analysis of the SONIC trial, Am J Gastroenterol, 115, 1236, 10.14309/ajg.0000000000000617

Feagan, 2013, The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis, Gastroenterology, 145, 149, 10.1053/j.gastro.2013.03.025

Bossuyt, 2020, Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density, Gut, 69, 1778, 10.1136/gutjnl-2019-320056

Takenaka, 2020, Development and validation of a deep neural network for accurate evaluation of endoscopic images from patients with ulcerative colitis, Gastroenterology, 158, 2150, 10.1053/j.gastro.2020.02.012

Yao, 2020, Fully automated endoscopic disease activity assessment in ulcerative colitis, Gastrointest Endosc, 93, 728, 10.1016/j.gie.2020.08.011

Bossuyt, 2021, Computer-aided diagnosis with monochromatic light endoscopy for scoring histologic remission in ulcerative colitis, Gastroenterology, 160, 23, 10.1053/j.gastro.2020.09.053

Lobatón, 2015, The modified Mayo endoscopic score (MMES): a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients, J Crohn's Colitis, 9, 846, 10.1093/ecco-jcc/jjv111

Jairath, 2017, Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis, Cochrane Database Syst Rev, 9

Bryant, 2016, Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up, Gut, 65, 408, 10.1136/gutjnl-2015-309598

Turner, 2020, STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD, Gastroenterology

Danese, 2020, Evolving therapeutic goals in ulcerative colitis: towards disease clearance, Nat Rev Gastroenterol Hepatol, 17, 1, 10.1038/s41575-019-0211-1

Christensen, 2017, Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes, Clin Gastroenterol Hepatol, 15, 1557, 10.1016/j.cgh.2017.02.016

Cushing, 2020, Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission, Aliment Pharmacol Ther, 51, 347, 10.1111/apt.15568

Magro, 2020, ECCO position paper: harmonization of the approach to ulcerative colitis histopathology, J Crohns Colitis, 14, 1503, 10.1093/ecco-jcc/jjaa110

Magro, 2020, Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis, J Crohns Colitis

Ma, 2018, Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis, Aliment Pharmacol Ther, 47, 1578, 10.1111/apt.14672

Magro, 2019, Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels, Gut, 68, 594, 10.1136/gutjnl-2017-315545

Bossuyt, 2020, Variability in the distribution of histological disease activity in the colon of patients with ulcerative colitis, J Crohns Colitis

Singh, 2018, Evolution of clinical trials in inflammatory bowel diseases, Curr Gastroenterol Rep, 20, 41, 10.1007/s11894-018-0648-3

Bhatt, 2013, Effect of platelet inhibition with cangrelor during PCI on ischemic events, N Engl J Med, 368, 1303, 10.1056/NEJMoa1300815

Léauté-Labrèze, 2015, A randomized, controlled trial of oral propranolol in infantile hemangioma, N Engl J Med, 372, 735, 10.1056/NEJMoa1404710

Rugo, 2016, Adaptive randomization of veliparib-carboplatin treatment in breast cancer, N Engl J Med, 375, 23, 10.1056/NEJMoa1513749

Sato, 2018, Practical characteristics of adaptive design in phase 2 and 3 clinical trials, J Clin Pharm Ther, 43, 170, 10.1111/jcpt.12617

Collignon, 2018, Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency, Trials, 19, 642, 10.1186/s13063-018-3012-x

Verstockt, 2021, Results of the Seventh Scientific Workshop of ECCO (III): precision medicine in IBD—disease outcome and response to therapy, J Crohns Colitis, 10.1093/ecco-jcc/jjab050

Ho, 2020, Ulcerative colitis: recent advances in the understanding of disease pathogenesis, F1000 Res, 9, 294, 10.12688/f1000research.20805.1

Seyed Tabib, 2020, Big data in IBD: big progress for clinical practice, Gut, 69, 1520, 10.1136/gutjnl-2019-320065

Fiocchi, 2020, What's new in IBD therapy: an “omics network” approach, Pharmacol Res, 159, 10.1016/j.phrs.2020.104886

Fiocchi, 2021, Results of the Seventh Scientific Workshop of ECCO: precision medicine in IBD—what, why and how, J Crohns Colitis, 10.1093/ecco-jcc/jjab051